The present review focuses on the utility of serum tumor markers in screening, diagnosis, prognosis and monitoring of pancreatic cancer. Serum determination of all tumor markers studied offers no help in screening or early diagnosis of pancreatic cancer. For diagnosis, blood group-related antigens, in particular CA 19-9, are considered the best indicators of this neoplasm. However, as occurs with other glycoproteic tumor markers, the circulating levels of CA 19-9 are significantly influenced by jaundice, probably because its liver metabolism is reduced. Therefore, the finding of elevated CA 19-9 levels in jaundiced patients has to be evaluated with caution. Since pancreatic cancer recurrences are not susceptible to treatment, the clinical role of widespread use of tumor marker determination in follow-up programs is limited and calls for a critical evaluation.
RaijmanI., LevinB.Exocrine tumors of the pancreas. In: GoV.L.W., Di MagnoE.P., GardnerJ.D., LebenthalE., ReberH.A., ScheeleG.A. eds. The pancreas: biology, pathobiology, and disease.New York: Raven Press, 1993; 899–912.
2.
GordisL., GoldE.B.Epidemiology and etiology of pancreatic cancer. In: GoV.L.W., Di MagnoE.P., GardnerJ.D., LebenthalE., ReberH.A., ScheeleG.A. eds. The pancreas: biology, pathobiology, and disease.New York: Raven Press, 1993; 837–55.
3.
SteinbergW.; The clinical utility of the CA 19-9 tumor-associated antigen.Am J Gastroenterol1990; 85: 350–5.
4.
FrebourgT., BercoffE., ManchonN.The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer.Cancer1988; 62: 2287–90.
5.
Lake-BakaarG., McKavanaghS., SummerfieldJ.A.Urinary immunoreactive trypsin excretion: a non-invasive screening test for pancreatic cancer.Lancet1979; ii: 878–80.
6.
FariniR., FabrisC., Del FaveroG.Role of the trypsin/creatinine clearance ratio in the differential diagnosis of chronic pancreatic disease.Gastroenterology1981; 81: 242–6.
7.
BassoD., FabrisC., MeaniA.Serum deoxyribonuclease and ribonuclease in pancreatic cancer and chronic pancreatitis.Tumori1985; 71: 529–32.
8.
YamamuraH., TatsutaM., ItoM.Effectiveness of discriminant analysis of serum CA 19-9 and elastase 1 in diagnosis of pancreatic carcinoma.Pancreas1989; 4: 401–5.
9.
BassoD., FabrisC., PanozzoM.P., MeggiatoT., Del FaveroG., NaccaratoR.Serum phospholipase A2 activity in chronic pancreatic diseases.Clin Biochem1990; 23: 229–32.
10.
Moller-PetersenJ., KlaerkeM., DatiF.Evaluation and comparison of cathodic trypsin-like immunoreactivity, pancreatic lipase and pancreatic isoamylase in the diagnosis of acute pancreatitis in 849 consecutive patients with acute abdominal pain.Clin Chim Acta1986; 157: 151–65.
11.
FabrisC., BassoD., Del FaveroG.Renal handling of amylase and immunoreactive trypsin in pancreatic cancer and chronic pancreatitis.Clin Physiol Biochem1990; 8: 30–7.
12.
JungeW., MalyuszM., EhrensH.J.The role of the kidney in the elimination of pancreatic lipase and amylase from blood.J Clin Chem Clin Biochem1985; 23: 387–92.
13.
HuhtalaM.L., KahanpaaK., SeppalaM., HalilaH., StenmanU.H.Excretion of a tumor associated trypsin inhibitor (TATI) into urine of patients with gynecological malignancy.Int J Cancer1983; 41: 493–9.
14.
TacconeW., MazzonW., BelliM.Evaluation of TATI and other markers in solid tumors.Scan J Clin Lab Invest1991; 51: 25–32.
15.
PlebaniM., BassoD., FabrisC.Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.Klin Wochenschr1989; 67: 1029–32.
16.
HigashiyamaM., MondenT., OgawaM.Immunohistochemical study on pancreatic secretory trypsin inhibitor (PSTI) in gastric carcinoma.Am J Clin Pathol1990; 93: 8–13.
17.
HigashiyamaM., DoiO., KodamaK.Immunohistochemical analysis of pancreatic secretory trypsin inhibitor expression in pulmonary adenocarcinoma: its possible participation in scar formation of the tumor tissues.Tumor Biol1992; 13: 299–307.
18.
OhmachiY., MurataA., MatsuuraN., YasudaT., UdaK., MoriT.Overexpression of pancreatic secretory trypsin inhibitor in pancreatic cancer.Int J Pancreatol1994; 15: 65–73.
19.
FabrisC., BassoD., Del FaveroG.Serum trypsin inhibitors in pancreatic cancer and chronic pancreatitis.Bull Cancer1989; 76: 145–7.
20.
CoonJ.S., WeinsteinR.S.Blood group-related antigens as markers of malignant potential and heterogeneity in human carcinomas.Human Pathol1986; 17: 1089–106.
TuoX., ItaiS., NishikataJ., MoriT., TanakaO., KannagiR.Stage-specific expression of cancer-associated type 1 and type 2 chain polylactosamine antigens in the developing pancreas of human embryos.Cancer Res1992; 52: 5744–51.
23.
ItaiS., AriiS., TobeR.Significance of 2-3 and 2-6 sialylation of Lewis A antigen in pancreas cancer.Cancer1988; 61: 775–87.
24.
OsakoM., YonezawaS., SiddikiB., HuangJ., HoJ.J.L., KimY.S., SatoE.Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors.Cancer1993; 71: 2191–9.
25.
SatomuraY., SawabuN., TakemoriY.Expression of various sialylated carbohydrate antigens in malignant and non malignant pancreatic tissues.Pancreas1991; 6: 448–58.
26.
IguroT., WakisakaA., TerasakiP.I.Sialylated Lewis X antigen detected in the sera of cancer patients.Lancet1984; ii: 817–8.
27.
SinnH-P, BrownS.A., OberleE., ThompsonJ.S.Analysis of the Lewis x epitope in human pancreas and pancreatic adenocarcinomas.Int J Pancreatol1992; 11: 125–35.
28.
OhtaH., SawabuN., TakemoriY.Measurement of sialylated stage-specific embryonic antigen-1 in pure pancreatic juice for the diagnosis of pancreatic cancer.Int J Pancreatol1994; 15: 35–41.
MagnaniJ.L., SteplewskiZ., KoprowskiH., GinsburgV.Identification of gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.Cancer Res1983; 43: 5489–92.
31.
HanssonG.C., ZopfD.Biosynthesis of the cancer-associated sialyl-Lea antigen.J Biol Chem1985; 260: 9388–92.
32.
KlugT.L., LeDonneN.C., GreberT.F., ZurawskiV.R.Purification and composition of a novel gastrointestinal tumor-associated glycoprotein expressing sialylated lacto-N-fucopentaose II (CA 19-9).Cancer Res1988; 48: 1505–11.
33.
KawaS., KatoM., OguchiH.Preparation and partial characterization of a pancreatic cancer-associated glycoprotein expressing CA 50.Scand J Gastroenterol1991; 26: 1307–18.
34.
LanM.S., BastR.C., ColnaghiM.I., KnappR.C., ColcherD., SchlomJ., MetzgarR.S.Co-expression of human cancer-associated epitopes on mucin molecules.Int J Cancer1987; 39: 68–72.
35.
KawaS., KatoM., OguchiH., KobayashiT., FurutaS., KanaiM.Preparation of pancreatic cancer-associated mucin expressing CA 19-9, CA 50, Span-1, Sialyl SSEA-1, and Dupan-2.Scand J Gastroenterol1991; 26: 981–92.
36.
IishiH., YamamuraH., TatsutaM., OkudaS., KitamuraT.Value of ultrasonographic examination combined with measurement of serum tumor markers in the diagnosis of pancreatic cancer of less than 3 cm in diameter.Cancer1986; 57: 1947–51.
37.
PiantinoP., AndriulliA., GindroT.CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.Am J Gastroenterol1986; 81: 436–9.
38.
SteinbergW.M., GelfandR., AndersonK.K.Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assay in detecting cancer of the pancreas.Gastroenterology1986; 90: 343–9.
39.
MalesciA., TommasiniM.A., BonatoC.Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.Gastroenterology1987; 92: 60–7.
40.
BeniniL., CavalliniG., ZordanD.A clinical evaluation of monoclonal (CA 19-9, CA 50, CA 12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer.Pancreas1988; 3: 61–6.
PleskowD.K., BergerH.J., GyvesJ., AllenE., McLeanA., PodolskyK.Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer.Ann Int Med1989; 110: 704–9.
43.
SafiF., RoscherR., BegerH.G.Tumor markers in pancreatic cancer.Sensitivity and specificity of CA 19-9. Hepato-Gastroenterol1989; 36: 419–23.
44.
MalesciA., MontorsiM., MarianiA.Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study.Pancreas1992; 7: 497–502.
45.
PlebaniM., BassoD., Del FaveroG.Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.Oncology1993; 50: 436–40.
46.
UhlenbruckG., HollerU., HeisingJ., van MilA., DienstC.Sialylated Lea blood group substances detected by the monoclonal antibody CA 19-9 in human seminal plasma and other organs.Urol Res1985; 13: 223–6.
47.
PourP.M., TemperoM.M., TakasakiH.Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type.Cancer Res1988; 48: 5422–6.
48.
von RosenA., LinderS., HermenbergU., PegertS.Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic diseases.Pancreas1993; 8: 160–5.
49.
AlbertM.B., SteinbergW.M., HenryJ.P.Elevated serum levels of tumor marker CA 19-9 in acute cholangitis.Dig Dis Sci1988; 33: 1223–5.
50.
BassoD., FabrisC., Del FaveroG.Combined determination of serum CA 19-9 and tissue polypeptide antigen: why no improvement in pancreatic cancer diagnosis?Oncology1988; 45: 24–9.
51.
PaganuzziM., OnettoM., MarroniP., BaroneD., ConioM., AsteH., PuglieseV.CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.Cancer1988; 61: 2100–8.
52.
OhshioG., ManabeT., WatanabeY., EndoK., KudoH., SuzukiT., TobeT.Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA 19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.Am J Gastroenterol1990; 85: 1370–6.
53.
BassoD., MeggiatoT., FabrisC., PlebaniM., FogarP., PanozzoM.P., Del FaveroG.Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases.Eur J Clin Invest1992; 22: 800–4.
54.
McFarlaneI.G.Hepatic clearance of serum glycoproteins.Clin Sci1983; 64: 127–35.
55.
KobataA.Structural changes induced in the sugar chains of glycoproteins by malignant transformation of producing cells and their clinical application.Biochimie1988; 70: 1575–85.
56.
BassoD., PlebaniM., PanozzoM.P.Concanavalin A affinity pattern of CA 19-9: an in vitro and in vivo study.Clin Chim Acta1994; 224: 219–21.
57.
LindholmL., HolmgrenJ., SvennerholmL.Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides.Int Arch Allergy Appl Immunol1983; 71: 178–81.
58.
NilssonO., ManssonJ.E., LindholmL., HolmgrenJ., SvennerholmL.Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody.FEBS Lett1985; 182: 398–402.
59.
KobayashiT., KawaS., TokooM.Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA 19-9 in the diagnosis of pancreatic cancer.Scan J Gastroenterol1991; 26: 787–97.
60.
LucarottiM.E., HabibN.A., KellyS.B.Clinical evaluation of combined use of CEA, CA 19-9, and CA 50 in the serum of patients with pancreatic carcinoma.Eur J Surg Oncol1991; 17: 51–3.
61.
BastR.C.Jr., FeeneyM., LazarusH., NadlerL.M., ColvinR.B., KnappR.C.Reactivity of a monoclonal antibody with human ovarian carcinoma.J Clin Invest1981; 68: 1331–7.
62.
HaglundC.Tumour marker antigen CA 125 in pancreatic cancer: a comparison with CA 19-9 and CEA.Br J Cancer1986; 54: 897–901.
63.
SakamotoK., HagaY., YoshimuraR., EgamiH., YokoyamaY., AkagiM.Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.Gut1987; 28: 323–9.
64.
LindholmL., JohanssonC., JanssonE.L., HallbergC., NilssonO.An immuno-radiometric assay (IRMA) for the CA 50 antigen. In: HolgrenJ. ed. Tumour marker antigen.Lund, Sweden: Studentlitteratur, 1985; 123–33.
65.
HaglundC., LindgrenJ., RobertsP.J., KuuselaP., NordlingS.Tissue expression of the tumour associated antigen CA 242 in benign and malignant pancreatic lesions.A comparison with CA 50 and CA 19-9. Br J Cancer1989; 60: 845–51.
66.
PasanenP.A., EskelinenM., PartanenK., PikkarainenP., PenttilaI., AlhavaE.Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.Anticancer Res1992; 12: 1689–94.
67.
RothlinM.A., JollerH., LargiaderF.CA 242 is a new tumor marker for pancreatic cancer.Cancer1993; 71: 701–7.
68.
MetzgarR.S., GaillardM.T., LevineS.J., TuckF.L., BossenE.H., BorowitzM.J.Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies.Cancer Res1982; 42: 601–8.
69.
TakasakiH., UchidaE., TemperoM.A., BurnettD.A., MetzgarR.S., PourP.M.Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.Cancer Res1988; 48: 1435–8.
70.
FabrisC., MalesciA., BassoD.Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.Br J Cancer1991; 63: 451–3.
71.
KawaS., OguchiH., KobayashiT., TokooM., FurutaS., KanaiM., HommaT.Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.Br J Cancer1991; 64: 899–902.
72.
PratM., BussolatiG., SpinnatoM.R., ComoglioP.M.Monoclonal antibodies against the human epidermoid carcinoma A 431.Cancer Detect Prevent1985; 8: 169–79.
73.
PratM., MorraI., BussolatiG., ComoglioP.M.CAR-3, a monoclonal antibody-defined antigen expressed on human carcinomas.Cancer Res1985; 45: 5799–807.
74.
PratM., MedicoE., PiantinoP., BrettiS., RossiniF.P., ComoglioP.M.The monoclonal antibody-defined CAR-3 antigen is a serological marker associated with pancreatic carcinoma.Int J Biol Markers1988; 3: 29–35.
75.
BassoD., PanozzoM.P., FabrisC.Does serum CAR-3 play a role in pancreatic cancer diagnosis?Oncology1991; 48: 22–5.
76.
ChungY.S., HoJ.J.L., KimY.S.The detection of human pancreatic cancer-associated antigen in the serum of cancer patients.Cancer1987; 60: 1636–43.
77.
KiriyamaS., HayakawaT., KondoT.Usefulness of a new tumour marker, span-1, for the diagnosis of pancreatic cancer.Cancer1990; 65: 1557–61.
78.
TakedaS., NakaoA., IchiharaT.Serum concentration and immunohistochemical localization of Span-1 antigen in pancreatic cancer.A comparison with CA 19-9 antigen. Hepato-Gastroenterol1991; 38: 143–8.
79.
PanucciA., FabrisC., Del FaveroG.Tissue polypeptide antigen (TPA) in pancreatic cancer diagnosis.Br J Cancer1985; 52: 801–3.
80.
MarinoP., BuccheriG., PreatoniA., FerrignoD., LuporiniA.C., PravettoniG.Tissue polypeptide specific antigen (TPS) and objective response to treatment in solid tumors.Int J Biol Markers1992; 7: 65–7.
81.
EscribanoM.J., CordierJ., NapM., Ten KateF.J.W., BurtinP.Differentiation antigens in fetal human pancreas.Reexpression in cancer. Int J Cancer1986; 38: 155–60.
82.
AlbersG.H.R., EscribanoM.J., GonzalesM., MulliezN., NapM.Fetoacinar pancreatic protein in the developing human pancreas.Differentiation1987; 34: 210.
83.
MazoA., FujiiY., ShimotakeJ., EscribanoM.J.Expression of fetoacinar pancreatic (FAP) protein in the pancreatic human tumor cell line BxPC-3.Pancreas1991; 6: 37–45.
84.
FujiiY., AlbersG.H.R., Carre-LlopisA., EscribanoM.J.The diagnostic value of the fetoacinar pancreatic protein in cancer of the pancreas: a comparative study with CA 19/9.Br J Cancer1987; 56: 495–500.
85.
AlbersG.H.R., EscribanoM.J., DaherN., NapM.An immunohistologic study of the feto-acinar pancreatic protein (FAP) in the normal pancreas, chronic pancreatitis, pancreatic adenocarcinoma, and intraabdominal metastases of adenocarcinomas.Am J Clin Pathol1990; 93: 14–9.
86.
BanwoO., VerseyJ., HobbsJ.R.New oncofetal antigen from human pancreas.Lancet1974; i: 643–5.
87.
GelderF.B., ReeseC.J., MoosaA.R., HallT., HunterR.Purification, partial characterization, and clinical evaluation of a pancreatic oncofetal antigen.Cancer Res1978; 38: 313–24.
88.
SchmiegelW.H., EberlW., KreikerC.Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.Hepato-gastroenterol1985; 32: 141–5.
89.
ItohT., KishiK., TojoM.Acinar cell carcinoma of the pancreas with elevated serum alpha-fetoprotein levels: a case report and a review of 28 cases reported in Japan.Gastroenterol Jpn1992; 27: 785–91.
90.
BerettaE., MalesciA., ZerbiA.Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer.Cancer1987; 60: 2428–31.
91.
BacD.J., KokT.C., van der GaastA., SplinterT.A.W.Evaluation of CA 19-9 serum levels for monitoring disease activity during chemotherapy of pancreatic adenocarcinoma.J Cancer Res Clin Oncol1991; 117: 263–5.
92.
NiederauC., GrendellJ.H.Diagnosis of pancreatic carcinoma.Imaging techniques and tumor markers. Pancreas1992; 7: 66–8.
93.
YoshimuraT., ManabeT., SuwaH.Nuclear DNA content as a prognostic predictor in carcinoma of the pancreas.Int J Pancreatol1993; 14: 29–36.
94.
ScialleroS., GiarettiW., GeidoE.DNA aneuploidy is an independent factor of poor prognosis in pancreatic and peripancreatic cancer.Int J Pancreatol1993; 14: 21–8.
95.
Del VillanoB.C., BrennanS., BrockP.Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.Clin Chem1983; 29: 549–52.
